CLLS vs MQT Comparison

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a diversified, closed-end investment management company. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S federal income taxes. The majority of its managed assets are invested in municipal bonds exempt from U.S. federal income taxes. The fund invests in municipal bonds that are in the three highest quality rating categories, or are deemed to be of comparable quality by the investment adviser at the time of investment. These are mainly long-term municipal bonds with maturities of more than ten years at the time of investment, having exposure to different sectors. The fund can also invest directly in such securities or synthetically through the use of derivatives.